Clinical trials: Hyperperfusion Syndrome
Carotid Artery Diseases, Carotid Atherosclerosis
Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning
Cerebral hyperperfusion syndrome (CHS) was initially described as a clinical complication following carotid endarterectomy (CEA), but it may occur after both CEA and carotid artery stenting.
- Conditions
- Carotid Artery Diseases, Carotid Atherosclerosis, Carotid Artery Stenosis, Cerebral Hyperperfusion Syndrome
- Trial name
- NCT05800821
- Testing
- Carotid revascularization
- Where
- Belarus
- Volunteers
- 500 people
- Sponsor
- State Institution "Republican Scientific and Practical Center" Cardiology, Belarus
Hyperperfusion Syndrome, Moyamoya Disease
Sevoflurane and Hyperperfusion Syndrome
The aim of the present study is to evaluate the effect of sevoflurane postconditioning on the incidence of postoperative hyperperfusion syndrome following revascularization surgery in moyamoya patients.
- Trial name
- NCT02510586
- Testing
- Sevoflurane
- Volunteers
- 152 people
- Sponsor
- Seoul National University Hospital
Carotid Stenosis, Cerebral Hyperperfusion Syndrome
Accuracy of TCD Monitoring in Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy
Background: Cerebral hyperperfusion syndrome (CHS) is a life threatening complication of carotid endarterectomy (CEA) and the changes of middle cerebral artery velocity are used to predict the occurrence of CHS but the accuracy…
- Conditions
- Carotid Stenosis, Cerebral Hyperperfusion Syndrome, Blood Pressure
- Trial name
- NCT01799070
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Cerebral Artery Stenosis, Carotid Artery Stent
Prediction of Hyperperfusion After Carotid Stenting by Multi-parameter Characteristics Based on Cerebral Autoregulation
Cerebral hyperperfusion syndrome (CHS) is one of the severe complication after carotid artery stenting with a high mortality rate.
- Conditions
- Cerebral Artery Stenosis, Carotid Artery Stent, Dynamic Cerebral Autoregulation
- Trial name
- HACASS (NCT06058676)
- Testing
- carotid artery stenting
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Xuanwu Hospital, Beijing
End Stage Liver DIsease, Portal Hypertension
Somatostatin in Living Donor Liver Transplantation
Aim of the study is to investigate the safety and the efficacy of somatostatin as liver inflow modulator in patients with end-stage liver disease (ESLD) and clinically significant portal hypertension (CSPH) undergoing…
- Trial name
- NCT04107428
- Testing
- Somatostatin
- Volunteers
- 56 people
- Sponsor
- King Faisal Specialist Hospital & Research Center